Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis

Pharmacotherapy

Volumn 30, Issue 7, 2010, Pages 741-748

  Mason, Molly A ^a   Shepler, Brian M ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Calcium carbonate; Sevelamer hydrochloride; Vascular calcification

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; SEVELAMER; CALCIUM; CALCIUM INTAKE; CALCIUM PHOSPHATE; PHOSPHATE; POLYAMINE;

BLOOD VESSEL CALCIFICATION; HEMODIALYSIS; HUMAN; MORBIDITY; MORTALITY; REVIEW; SURVIVAL RATE; CALCINOSIS; CALCIUM INTAKE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; CORONARY ARTERY DISEASE; DISEASE COURSE; HYPERPHOSPHATEMIA; RENAL REPLACEMENT THERAPY; THERAPEUTIC USE;

CALCINOSIS; CALCIUM; CALCIUM PHOSPHATES; CALCIUM, DIETARY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; HYPERPHOSPHATEMIA; PHOSPHATES; POLYAMINES; RENAL DIALYSIS;

EID: 77954112154     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.7.741     Document Type: Review

References (33)

1. Go A, Chertow G, Fan D, McCulloch C, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Eng J Med 2004;351:1296-308.
2. National Institute of Diabetes and Digestive and Kidney Diseases. U.S. renal data system 2009 annual report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
3. Raggi P, Boulay A, Chassan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. J Am Coll Cardiol 2002;39:695-701.
4. National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
5. Marchais S, Metivier F, Guerin AP, London GM. Association of hyperphosphatemia with haemodynamic disturbances in end stage renal disease. Neph Dial Transplant 1999;14:2178-83.
6. Frazao J, Adragao T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney Int 2008;75:S38-43.
7. Spasovski G. Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 2007;39:1209-16.
8. Blacher J, Guerin A, Pannier B, Marchais S, London G. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42. (Pubitemid 34258697)
9. Ketteler M, Gross M, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int 2005;67:S120-7.
10. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitier E, Luft F. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401. (Pubitemid 26075849)
11. Goodman W, Goldin J, Kuizon B, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Eng J Med 2000;342:1478-83.
12. Hunt J, Fairman R, Mitchell M, et al. Bone formation in carotid plaques a clinicopathological study. Stroke 2002;33:1214-19.
13. London G, Guerin A, Marchais S, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40.
14. Amann K, Gross M, London G, Ritz E. Hyperphosphatemia: a silent killer with renal failure? Nephrol Dial Transplant 1999;14:2085-7.
15. Izumi M, Morita S, Nishian Y, et al. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films. Ren Fail 2008;30:952-8.
16. Raggi P. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin Nephrol 2000;54:325-33.
17. Savica V, Calo L, Monardo P, Santoro D, Bellinghieri G. Phosphate binders and management of hyperphosphatemia in end-stage renal disease. Nephrol Dial Transplant 2006;21:2065-8.
18. Mai M, Emmett M, Sheikh M, Santa Ana C, Schiller L, Fordtran J. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989;36:690-5.
19. Locatelli F, Cannata-Andia J, Drueke T, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-31. (Pubitemid 34521119)
20. Braun J, Asmus H, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-15.
21. Chertow G, Burke S, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
22. Chertow G, Raggi P, McCarthy J, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14.
23. Raggi P, Bommer J, Chertow G. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004;13:134-41.
24. Block G, Spiegel D, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24.
25. Galassi A, Spiegel D, Bellasi A, Block G, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006;21:3215-22.
26. Takei T, Otsubo S, Uchida K. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract 2008;108:c278-83.
27. Qunibi W, Moustafa M, Muenz L, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the calcium acetate Renagel evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65.
28. Barreto D, Barreto F, Carvalho A, et al. Phosphate binder impact on bone remodeling and coronary calcification: results from the BRiC study. Nephron Clin Pract 2008;110:c273-83.
29. Asmus H, Braun J, Krause R, et al. Two-year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005;20:1653-61.
30. Jean G, Bresson E, Terrat J, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009;24:948-55.
31. Block G, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41.
32. Suki W, Zabaneh R, Cangiano J, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7.
33. St. Peter W, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the dialysis clinical outcomes revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008;51:445-54.